PER-069-01
Completed
未知
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,0 sites0 target enrollmentStarted: November 19, 2001Last updated:
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 to 0 (—)
Inclusion Criteria
- •1\. The subject must have a documented colonoscopy of the blind man (documented by means of a photograph) made by a physician related to the study with adequate preparation, resulting in the diagnosis and clearance of an adenomatous polyp within a period of 4 months (120 days) before randomization (90 days between the colonoscopy and the Initial period).
- •2\. In the basal colonoscopy, the subject must have one of the following requirements, documented:
- •A. An adenomatous polyp\> 6 mm; confirmed by the colonoscopy report and documented
- •B. Two or more adenomatous polyps (up to a maximum of 10\) of any size documented by a local pathology laboratory report plus the colonoscopy report.
- •C. If the colonoscopy report indicates that any polyp of any size was left in the subject, the subject is not eligible.
- •D. If the colonoscopy report does not specifically indicate that all visible adenomas were removed, but does not describe that any adenoma may have been left inside, the subject is eligible if it meets the criteria of A or B.
- •3\. The subject must be 30 years of age or older.
- •4\. The subject is willing to abstain from the chronic use of all NSAIDs or COX\-2 inhibitors, excluding aspirin at cardiovascular doses of \<162\.5 mg PO QD or 325 mg PO QOD, for the entire duration of the study. The chronic use of NSAIDs is defined as a frequency of 7 consecutive days (1 week) for\> 3 weeks a year or more than 21 days throughout the year.
- •5\. The duration of the anticipated use of oral / endovenous corticosteroids by the subject throughout the 6\-month period should be less than 2 weeks.
- •6\. The anticipated use of orally inhaled steroids by the subject over a period of 6 months should be less than 4 weeks. If the chronic use of inhaled steroids nasally is necessary, the subject should commit to using mometasone (Nasonex®). The use of mometasone is not restricted. In countries where mometasone (Nasonex®) is not available, fluticasone (Flonase®) will only be allowed. Subjects can be switched to mometasone, but they must have discontinued the previous nasal steroid for at least 30 days before randomization. The change must be made during or before the Initial Placebo visit.
Exclusion Criteria
- •1\. The subject has had a history of familial adenomatous polyposis or non\-hereditary polyposis colorectal cancer
- •2\. The subject has a history of inflammatory bowel disease.
- •3\. The subject has chronic or acute renal or hepatic impairment, a significant alteration of hemorrhages, or any other condition that in the opinion of the investigator prevents their participation in the study throughout the duration of the trial.
- •4\. The subject has a history of hypersensitivity to COX\-2 inhibitors, NSAIDs, salicylates or sulfonamides.
- •5\. Subject has a history of resection of the large intestine excluding appendectomy.
- •6\. The subject has used NSAIDs, excluding aspirin at a cardiovascular dose (eg,
- •\<162\.5 mg PO per day or 325 mg interdiario), at a frequency equal to or greater than three times a week during the two months (60 days) prior to randomization.
- •7\. The subject has received treatment for gastrointestinal ulcer in the month prior to the Initial stage.
- •8\. The subject has a history of invasive cancer during the past five years (excluding non\-melanoma skin cancer).
- •9\. Subject has received an investigational medication within 30 days prior to randomization or is scheduled to receive an investigational drug other than celecoxib during the course of the study.
Investigators
Similar Trials
Not yet recruiting
Phase 4
A study to compare efficacy of injection of Ropivacaine plus Fentanyl and Ropivacaine plus Tramadol in spinal anaesthesiaHealth Condition 1: K353- Acute appendicitis with localizedperitonitisHealth Condition 2: N211- Calculus in urethraHealth Condition 3: N701- Chronic salpingitis and oophoritisHealth Condition 4: S720- Fracture of head and neck of femurHealth Condition 5: S828- Other fractures of lower legHealth Condition 6: K409- Unilateral inguinal hernia, without obstruction or gangreneCTRI/2023/06/053362Pacific medical college and hospital
Recruiting
Phase 1
Clinical study on Alkaline Water in healthy subjectsCTRI/2024/06/068585Hydron Alkaline Aqua Pvt. Ltd.
Completed
Not Applicable
A Clinical Trial of Levocarnitine to Treat Autism Spectrum DisordersAutism Spectrum Disorder (ASD)Mental and Behavioural DisordersPervasive developmental disordersISRCTN54273114Autism Research Institute (USA)30
Recruiting
Phase 1
Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular EdemaITMCTR2000003673Eye Hospital, China Academy of Chinese Medical Sciences
Terminated
Phase 2
ox 1 and 4 inhibition in type 1 diabetic kidney diseasediabetic kidney diseasetype 1 diabetesMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseACTRN12617001187336Baker Heart and Diabetes Institute83